 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nordea Investment Management AB increased its position in Vir Biotechnology, Inc. (NASDAQ:VIR  Free Report) by 2.3% in the 2nd quarter, according to its most recent 13F filing with the...

Nordea Investment Management AB Acquires 3,415 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine Phase 1 trial supported by the Bill & Melinda Gates Foundation...

Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV

Vir Biotechnology (NASDAQ:VIR  Get Free Report) was downgraded by research analysts at Bank of America from a buy rating to a neutral rating in a report released on...

Bank of America Downgrades Vir Biotechnology (NASDAQ:VIR) to Neutral

Vir Biotechnology, Inc. (NASDAQ:VIR  Get Free Report) shares hit a new 52-week low during trading on Tuesday . The stock traded as low as $12.10 and last traded at $12.15, with a volume of...

Vir Biotechnology (NASDAQ:VIR) Reaches New 12-Month Low at $12.10

This indicator may be signaling that VIR's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Vir Biotechnology (VIR, $12.25) entered Downtrend as Momentum indicator drops below 0 level on Sep 05, 2023

This is a signal that VIR's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Vir Biotechnology (VIR, $12.25) RSI Indicator left the oversold zone on September 05, 2023

Investors considering a purchase of Vir Biotechnology Inc (VIR) stock, but tentative about paying the going market price of 12.21/share, might benefit from considering selling puts among the...

Commit To Buy Vir Biotechnology At $10, Earn 13.4% Annualized Using Options

Guggenheim Capital LLC raised its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR  Free Report) by 194.5% in the 1st quarter, according to the company in its most recent 13F filing with the...

Guggenheim Capital LLC Acquires 34,592 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Swiss National Bank trimmed its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR  Free Report) by 10.3% during the first quarter, according to its most recent disclosure with the Securities...

Swiss National Bank Sells 18,100 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Vir Biotechnology (VIR, $12.65) entered Downtrend as Momentum indicator drops below 0 level on Aug 31, 2023

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Watchers	5,939
52-Wk Low	$8.90
52-Wk High	$31.55

Market Cap	$1.24B
Volume (M)	1.12M
52-Wk High	$31.55
52-Wk Low	$8.90

Current Price	$9.21
Prev Close	$9.26
Open	$9.25
Dividend Yield	0.00%
50-Day Moving Average	$12.17
Beta	1.10
Avg. Volume	1.02M
PE Ratio	-4.67

52-Week High	$31.55
52-Week Low	$8.90
Market Capitalization	$1.24B
EPS	-$1.97
Price to Book	0.68
Revenue Per Employee	$851,946.18
Enterprise Value/EBITDA	-5.80

VIR Vir Biotechnology Inc

About

Feed

News

Sentiment

Earnings

Fundamentals